Company
Melbourne, VIC
Every investor coverage indicates participated in a round Royal Victorian Eye and Ear Hospital raised.
Companies Royal Victorian Eye and Ear Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Royal Victorian Eye and Ear Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.
Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au
Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.